Menopause: what it is, the age it usually starts, how long it lasts, and the long-term changes that follow

Short Answer

Menopause is the point when your menstrual periods have stopped permanently: clinically, it is reached after 12 consecutive months with no period when pregnancy, illness, medication, surgery, or another cause is not explaining the bleeding change. It is not a years-long "stage" you stay in; it is a defined point in time that marks the end of the reproductive years. The years of irregular cycles and shifting symptoms before that point are perimenopause. Everything after it is postmenopause. For most people, natural menopause happens in midlife — most commonly between 45 and 55, with the U.S. average reported around the early 50s (WHO).

What usually makes the transition feel confusing is that the hormone change starts before the "official" menopause date. As ovarian follicle function declines, estrogen levels fall and fluctuate, and your body can show it through hot flashes, night sweats, disrupted sleep, mood changes, brain fog, vaginal and urinary symptoms, and changes in periods. Over the longer term, lower estrogen is also part of why bone and cardiovascular health need more attention after the transition: studies describe rapid bone loss around the final menstrual period, and heart and stroke risk rises at and around menopause, with some SWAN data pointing to late perimenopause as a window when vascular changes may become more visible (WHO).

Menopause at a glance

The common symptoms of menopause

Menopause symptoms are the body's response to changing ovarian hormones — especially the drop and fluctuation in estrogen and progesterone. For some people, that shows up loudly as hot flashes and night sweats. For others, it looks more like broken sleep, mood changes, brain fog, or a body that starts storing more fat around the abdomen even if the scale has not changed much. You may have many symptoms, a few, or almost none; the pattern can also change over time (MedlinePlus).

• Vasomotor — Hot flashes and night sweats: sudden waves of heat, flushing, and sweating, often around the face, neck, and chest. In a nationally representative U.S. survey of women ages 40–65, vasomotor symptoms were reported by 79% of perimenopausal women and 65% of postmenopausal women (PubMed 18202963).

• Sleep — Trouble falling asleep, waking in the night, or waking after a night sweat and not being able to get back to sleep. Over time, poor sleep can feed fatigue and memory problems (MedlinePlus).

• Mood & cognition — Mood swings, irritability, anxiety, low mood, difficulty concentrating, memory slips, or "brain fog." These can come from hormone shifts directly, but they often get worse when sleep is repeatedly interrupted (MedlinePlus).

• Body composition — More central or abdominal fat, especially visceral fat around the organs. In SWAN data, visceral fat increased by 6.24% per year during the menopause transition in the reference group, while android fat increased by 5.54% per year; waist size changed more gradually, so the shift may be partly hidden (PMC8372653).

• Long-term — Bone and cardiovascular changes are often silent at first. Bone-density loss accelerates in late perimenopause and the first postmenopausal years, while the American Heart Association describes the menopause transition as a period of higher cardiometabolic and vascular vulnerability, with increases in LDL cholesterol, metabolic-syndrome risk, and vascular remodeling (PMC2266953).

What menopause actually is

Menopause is not a phase that drags on for years — it is a single point in time. Clinically, you have reached menopause after 12 consecutive months without a menstrual period, as long as the bleeding has not stopped because of another cause, such as pregnancy, a medication, or a medical condition. The months or years before that point are perimenopause, also called the menopausal transition. The time after that 12-month mark is postmenopause (NICHD).

That distinction matters because "how long menopause lasts" is often the wrong question. The menopause date itself is identified only in hindsight, after a full year without a period. What can last for years is the transition around it: cycles may become unpredictable, sleep may change, hot flashes or night sweats may appear, and your body may start responding differently to stress, heat, alcohol, exercise, or poor sleep (MedlinePlus).

The underlying driver is hormonal. As the ovaries wind down, they make less estrogen and progesterone; those shifts affect the brain's temperature regulation, sleep, mood, the vaginal and urinary tissues, metabolism, and bone turnover. In the research literature the transition is described this way: "The hormonal fluctuations and irregular ovulation can cause vasomotor symptoms (i.e., hot flashes, night sweats), sleep disturbances, mood and cognition issues, and increased risk of visceral adiposity" (Pangalangan & Tollefson, 2025).

Perimenopause is the lead-in to that final period, not a separate destination: "Perimenopause encompasses the transitional years preceding menopause (the final menstrual period)" (Pangalangan & Tollefson, 2025).

When menopause starts and how long it lasts

Most women reach natural menopause in the early 50s. In the U.S., the average age is commonly given as about 51, while the most common window is 45 to 55; population studies in high-income countries put the typical age close to 49–52, with a median around 51.4. Menopause is not a years-long process in the strict medical sense. It is the point you reach after 12 months in a row without a period, vaginal bleeding, or spotting — which is why you usually recognize it only in hindsight (Mayo Clinic).

That's why the question how long does menopause last? needs a careful answer. The "menopause" milestone is one point in time; the body changes around it can take years. Perimenopause — the run-up to that final period — can begin in your 40s, sometimes earlier, as estrogen rises and falls unevenly. Periods may get closer together, farther apart, heavier, lighter, or skipped altogether before they stop (Mayo Clinic).

Symptoms also do not switch off the day periods stop. Hot flashes and night sweats, in particular, can last well into postmenopause because the brain's temperature-control system is still adapting to a different hormone environment. In the SWAN cohort, among women with frequent vasomotor symptoms, the median total duration was 7.4 years, and symptoms persisted for a median of 4.5 years after the final menstrual period (PubMed 25686030). So for many people, the lived experience is not "menopause lasts one year," but "the transition and symptoms may stretch across several years."

If periods stop before age 40, clinicians treat that as a different situation. Premature menopause means menopause before 40. Primary ovarian insufficiency (POI) also involves the ovaries not working normally before 40, but it is not exactly the same as natural menopause: ovarian function can be intermittent, so periods and even pregnancy may still happen. Either way, symptoms or cycle changes before 40 deserve medical evaluation rather than being dismissed as "just early menopause" (MedlinePlus).

The long-term changes: bone and heart

The part of menopause that gets the least airtime is often the most important: the years after estrogen falls. Hot flashes and irregular periods may be what you notice first, but the quieter shift is happening in blood vessels and bone. Estrogen helps support vascular function, lipid metabolism, and bone remodeling; when ovarian estrogen drops, those systems no longer get the same signal.

Heart. Before menopause, women tend to have a measurable cardiovascular advantage over men of the same age, and that protection narrows after menopause. Reviews of estrogen and vascular biology describe this protection as progressively lost in the years after menopause, while newer cardiovascular reviews frame the menopause transition as a period when risk factors can start clustering: blood pressure, cholesterol, insulin resistance, body-fat distribution, inflammation, and vascular stiffness can all move in the wrong direction (PubMed 11903309). In a blood-pressure modeling analysis, the authors note that "female protection is lost after menopause, the onset of which marks the beginning of a rapid decline in estrogen levels" (Layton, PMID 41483838).

That is not just about blood pressure. A contemporary review of menopause and cardiovascular risk puts it directly: "The risk of atherosclerotic heart disease accelerates during the menopause transition due to hormonal, metabolic, and vascular changes" (PMC12511246).

Which is exactly why this window is worth treating as a prevention opportunity rather than a passive event: "Menopause is an important period to implement prevention strategies to reduce future incidence CVD" (PMC12511246).

Bone. Bone changes follow the same logic: less estrogen means bone is broken down faster than it is rebuilt. The North American Menopause Society states that postmenopausal bone loss related to estrogen deficiency is the primary contributor to osteoporosis, and osteoporosis raises the risk of fractures that can carry long-term disability and mortality risk (PubMed 34448749). NIH's National Institute on Aging explains the pattern plainly: around menopause, women may lose bone mass quickly for several years; after that, loss slows but continues (NIA).

The fastest loss tends to cluster around the final menstrual period, not decades later. In SWAN data, bone mineral density loss was greatest from about 1 year before through 2 years after the final menstrual period (PubMed 21976317). Other longitudinal data show the same shape: vertebral bone loss accelerated sharply during menopause, with reported average annual changes around −2.35% in perimenopause and about −2.34% in the first 1–2 years after menopause, then easing after roughly 3 years (PubMed 8504369). Another review of menopause-transition bone data reported lumbar-spine loss rising from 1.7% per year in perimenopause to 3.3% per year during the two years after the final menstrual period, then declining to 1.1% per year in later postmenopause (PMC3920744).

This is why postmenopause is not just "after the symptoms." It is a new risk landscape. Your clinician may think about blood pressure, lipids, glucose, smoking, family history, movement, fall risk, and whether you need bone-density screening. The goal is not to medicalize menopause. It is to catch the body's new direction early enough to protect your heart, bones, and independence.

Treatment and symptom management

Menopause is a normal life stage, not a disease. But "normal" does not mean you have to white-knuckle through hot flashes, night sweats, broken sleep, vaginal pain, mood swings, or the longer-term shifts in bone and cardiovascular risk. The goal is not to "treat menopause away." It is to reduce the symptoms that are wearing down your day-to-day life and to protect the body systems that lose some estrogen support after the transition.

Menopausal hormone therapy (MHT/HRT). For moderate-to-severe hot flashes and night sweats, menopausal hormone therapy is still considered the most effective treatment; it can also help with genitourinary symptoms of menopause and help prevent bone loss in the right person. Safety is not one-size-fits-all: risk depends on the type of hormone, dose, duration, route of administration, whether a progestogen is needed, and when treatment starts relative to menopause. Any hormone therapy is individualized by a clinician — do not self-start or self-adjust it. The 2022 North American Menopause Society position statement reports a more favorable benefit-risk profile for women who are younger than 60 or within 10 years of menopause onset and have no contraindications; starting after age 60 or more than 10 years after menopause tends to carry a less favorable profile because absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia rise with age and time since menopause (PubMed 35797481).

A cardiovascular-risk review notes that older oral synthetic regimens carried more risk than modern options: "Contemporary formulations such as low-dose transdermal estrogen and micronized progesterone have lower cardiovascular risk" (PMC12511246). That is why the conversation with a clinician should be specific: not just "hormones or no hormones," but which formulation, which route, whether you still have a uterus, how long it has been since your final period, and what your personal history looks like. The FDA says menopausal hormone therapy is not for everyone and lists reasons not to use it, including possible pregnancy, unexplained vaginal bleeding, certain cancers, previous stroke or heart attack, blood clots, and liver disease (FDA). Do not start, stop, or change hormone therapy without a clinician.

Non-hormonal options. If MHT is not a fit — because of medical history, risk factors, side effects, or personal preference — you still have evidence-based options. The 2023 North American Menopause Society nonhormone position statement recommends several approaches for vasomotor symptoms, including cognitive behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant, oxybutynin, weight loss in some people, and stellate ganglion block in selected cases; it also notes that hormone therapy remains the most effective option and that nonhormonal care matters especially when hormones are contraindicated or unwanted (PubMed 37252752).

Fezolinetant is a newer nonhormonal option: the FDA approved it in 2023 for moderate-to-severe vasomotor symptoms due to menopause, and it works through neurokinin-3 receptor signaling in the brain's temperature-regulation system rather than by replacing estrogen (FDA). Because the FDA later added a warning about rare but serious liver injury with fezolinetant, this is not a "casual supplement" choice; it needs prescribing, screening, and monitoring by a clinician (FDA).

Lifestyle measures also play a real role, not because they "fix hormones," but because they lower the load on systems menopause can strain: sleep regulation, vascular reactivity, weight, glucose control, mood, muscle, and bone. A lifestyle-medicine review of the transition reports outcomes including "reductions in vasomotor symptoms, improved sleep quality, enhanced mental well-being, healthier weight regulation, and reduced cardiometabolic and osteoporosis risk" (Anekwe et al., PMID 40937901).

The practical takeaway: build a plan around your main problem. If night sweats are wrecking sleep, that is a treatment target. If vaginal dryness or pain is making sex or daily comfort difficult, that is a treatment target. If you have early menopause, severe symptoms, osteoporosis risk, migraine, clotting history, breast cancer history, high blood pressure, or heart disease risk, your plan needs tighter medical tailoring. Specific non-hormonal drug choices and doses — including SSRIs/SNRIs, gabapentin, oxybutynin, or neurokinin-3 receptor antagonists — should be discussed with a clinician, because the right option depends on your symptoms, other medications, liver health, fall risk, sleep pattern, mood history, and cardiovascular risk.

What your heart rate and sleep data can show

Menopause is one of the few life stages where a wearable can help make an internal transition visible. It cannot diagnose menopause for you, and it cannot tell you what treatment you need. But it can show the body-level pattern behind a vague, frustrating feeling: sleep is less solid, recovery looks different, your resting heart rate may not behave the way it used to, and HRV may trend lower as ovarian hormones change.

Heart rate variability, or HRV, is one way to estimate how your autonomic nervous system is balancing effort and recovery. That system helps regulate heart rate, blood vessel tone, temperature responses, and stress physiology — the same terrain many people feel shifting during the menopausal transition. A living systematic review of wearable-derived HRV found that "HRV tended to decline after menopause with increasing age" (de Jager et al., PMID 41545627).

The same review quantified how much HRV can move with ovarian-hormone changes across the menstrual cycle, which matters because it gives your own numbers context. A small HRV change is not automatically a problem; sometimes it is physiology doing what physiology does. In naturally menstruating females, the review described "differences in time-domain HRV ranging from 3 to 9%" across the cycle (de Jager et al., PMID 41545627).

This is where tracking earns its place. Night sweats can disrupt sleep, and sleep problems are common during the menopausal transition; when sleep breaks into pieces, the next day often feels like low energy, worse mood, brain fog, or a body that never quite recovered overnight (MedlinePlus). At the same time, estrogen decline is tied to changes in cardiac autonomic regulation, so HRV and resting-heart-rate patterns may shift along with symptoms (PubMed 24329696).

The value is not in one "bad" night or one low HRV score. It is in the pattern. If your data shows weeks of more fragmented sleep, lower overnight HRV, higher resting heart rate, or slower recovery — especially alongside hot flashes, cycle changes, palpitations, fatigue, or mood changes — you have something concrete to bring to a clinician instead of trying to explain, "I just don't feel like myself." Welltory tracks and records these patterns; it does not diagnose menopause or any condition.

When to see a doctor

See a clinician if your periods stop or become widely spaced before age 40, because that can point to primary ovarian insufficiency or premature menopause rather than the usual menopause transition. It's also worth booking a visit if you're younger than 45 and your cycle starts skipping for long stretches, your bleeding becomes very heavy, your periods last longer than usual, or your symptoms feel out of proportion for you. The goal isn't to "prove" menopause with one lab number; it's to make sure pregnancy, thyroid disease, anemia, medication effects, and other treatable causes aren't being missed. Menopause is usually diagnosed from your age, your period pattern, and your symptoms. For otherwise healthy people aged 45 or older with typical menopause symptoms, NICE recommends identifying perimenopause or menopause without routine laboratory tests; FSH testing can be less useful in perimenopause because hormones fluctuate, and NICE specifically warns against using FSH to identify menopause in people using combined estrogen-progestogen contraception or high-dose progestogen (Cleveland Clinic).

Bleeding after menopause is different. If you've gone 12 months with no period and then have any vaginal bleeding — even spotting, pink or brown discharge, or a one-time episode — get checked. Most causes are not cancer, but postmenopausal bleeding always needs evaluation because it can be an early sign of womb or ovarian cancer and is easier to treat when found early. You should also ask for help if hot flashes, night sweats, insomnia, vaginal pain or dryness, brain fog, anxiety, low mood, or irritability are disrupting sleep, work, relationships, sex, or daily life; suffering through symptoms is not a requirement of menopause. New palpitations should be discussed too — and if they come with chest pressure or pain, fainting, severe shortness of breath, dizziness, unusual sweating, or pain spreading to the jaw, neck, back, or arm, seek immediate emergency medical care (NHS).

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data